Patients with underlying metabolic dysfunction, such as type 2 diabetes mellitus and obesity, are at a higher risk for COVID-19 complications, including multi-organ dysfunction, secondary to a deranged immune response, and cellular energy deprivation. These patients are at risk of chronic inflammation associated with increased susceptibility to the severe immune manifestations of COVID-19. The altered metabolic profile and energy generation of immune cells affect their activation, exacerbating the imbalanced immune response. Now, scientists have discovered why and how this occurs with findings paving the way for better treatments in the future.
“We know that there are a range of immune responses to COVID-19, and the biological processes underlying those responses are not well understood,” said co-first author Jihoon Lee, a graduate student at Fred Hutchinson Cancer Research Center.
He continued: “We analysed thousands of biological markers linked to metabolic pathways that underlie the immune system and found some clues as to what immune-metabolic changes may be pivotal in severe disease.
“Our hope is that these observations of immune function will help others piece together the body’s response to COVID-19.
“The deeper understanding gained here may eventually lead to better therapies that can more precisely target the most problematic immune or metabolic changes.”
“We have found metabolic reprogramming that is highly specific to individual immune cell.
“These classes and even cell subtypes, and the complex metabolic reprogramming of the immune system is associated with the plasma global metabolome and are predictive of disease severity and even patient death,” added co-first and co-corresponding author Dr Yapeng Su, a research scientist at Institute for Systems Biology.
“Such deep and clinically relevant insights on sophisticated metabolic reprogramming within our heterogeneous immune systems are otherwise impossible to gain without advanced single-cell multi-omic analysis.”
Dr Jim Heath, president and professor of ISB and co-corresponding author on the paper said: “This work provides significant insights for developing more effective treatments against COVID-19.
“It also represents a major technological hurdle.
“Many of the data sets that are collected from these patients tend to measure very different aspects of the disease and are analysed in isolation.
“Of course, one would like these different views to contribute to an overall picture of the patient.
“The approach described here allows for the sum of the different data sets to be much greater than the parts, and provides for a much richer interpretation of the disease.”